|本期目录/Table of Contents|

[1]杜娟,徐莉,牟娅妮,等.乳双歧杆菌Bb12辅助治疗儿童功能性便秘疗效分析[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):610-613.[doi:10.3969/j.issn.1672-271X.2021.06.011]
　DU Juan,XU Li,MOU Ya-ni,et al.Effects of Bifidobacterium lactis Bb12 in the adjuvant treatment of functional constipation in children[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(6):610-613.[doi:10.3969/j.issn.1672-271X.2021.06.011]
点击复制

乳双歧杆菌Bb12辅助治疗儿童功能性便秘疗效分析()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年6期
页码:
610-613
栏目:
临床研究
出版日期:
2021-12-15

文章信息/Info

Title:
Effects of Bifidobacterium lactis Bb12 in the adjuvant treatment of functional constipation in children
作者:
杜娟; 徐莉; 牟娅妮; 周亚红; 许可青
作者单位：213011常州，常州市第七人民医院儿科（杜娟、徐莉、周 亚红），综合实验室（许可青）；200062 上海，上海交通大学医学院附属上海儿童医院消化科（牟娅妮）
Author(s):
DU Juan;  XU Li;  MOU Ya-ni ;  ZHOU Ya-hong ;  XU Ke-qing
(1.Department of Pediatrics,Changzhou Seventh People’s Hospital,Changzhou 213011, Jiangsu,China;2.Department of Gastroenterology,Shanghai Children’s Hospital Affiliated to Medical College of Shanghai Jiaotong University,Shanghai 200062, China;3.General Laboratory, Changzhou Seventh People’s Hospital, Changzhou 213011, Jiangsu, China)
关键词:
益生菌; 乳果糖; 功能性便秘; 儿童
Keywords:
probiotics;  lactulose;  functional constipation;  children
分类号:
R725.7
DOI:
10.3969/j.issn.1672-271X.2021.06.011
文献标志码:
A
摘要:
目的探讨乳双歧杆菌Bb12辅助治疗儿童功能性便秘（FC）的疗效。方法选择2018年3月至2019年7月期间就诊 于常州市第七人民医院便秘门诊的FC患儿，根据随机对照表分为联合组38例及对照组32例。联合组给予Bb12及乳果 糖联合治疗4周；对照组给予乳果糖治疗4周，填写调查问卷及随访表格，观察患儿治疗后4周内服药情况（是否服药 、具体剂量、有无不良反应等）和便秘情况（病程、排便频率、粪便的Bristol分型、便秘伴随症状等 )，每2周便 秘门诊随访，电话随访患儿治疗后第8周的便秘情况。比较2组治疗第4周和第8周的临床疗效。结果联合组患儿抗拒 排便表现较对照组更为显著（73.68% vs 36.67%，P＜0.05）。治疗前联合组粪便Bristol分型平均为Ⅰ～Ⅱ型，对 照组为Ⅱ～Ⅲ型，联合组较对照组粪便性状更为干燥坚硬（P＜0.05）。2组治疗后排便频率均较治疗前显著增加、 粪便性状均较前软化（P＜0.05）；治疗后第3周及第4周联合组排便频率[(4.81±1.43)、(4.81±1.68)次/周]高于 对照组[(3.97±1.58)、(4.03±1.33)次/周，P＜0.05]；治疗后第4周2组粪便Bristol分型平均为Ⅳ型，组间比较差 异无统计学意义（P>0.05）。2组治疗后第4周临床疗效比较差异无统计学意义（P>0.05），治疗后第8周联合组临床 疗效优于对照组（97.37% vs62.50%，P＜0.01）。结论乳双歧杆菌Bb12辅助治疗儿童功能性便秘有效。
Abstract:
ObjectiveTo discuss the efficacy of Bifidobacterium lactis Bb12 in the adjuvant treatment of functional constipation (FC) in children.MethodsThis study was a randomized controlled study. A total of 70 children with FC were enrolled in the constipation clinic of Changzhou Seventh People’s Hospital, 38 cases in the joint group, 32 cases in the control group. The joint group was treated with Bb12 and lactulose for 4 weeks, while the control group was treated with lactulose for 4 weeks. With the questionnaire and follow-up form, we observed the medication of the children within 4 weeks after treatment (whether to take medicine, specific dose, whether there were adverse reactions, etc) and constipation (course of disease, bowel movements per week, Bristol typing of feces and constipation with symptoms, etc), and visited the constipation clinic every 2 weeks. The constipation of the children was followed up by telephone at the 8th week after treatment. The clinical effects of the two groups were compared at the 4th and 8th week after treatment.ResultsThe resistance to defecation in the joint group was more significant than that in the control group (73.68% vs 36.67%, P<0.05). Before the treatment, the average BSFS in the joint group was type Ⅰ - Ⅱ and that in the control group was type Ⅱ - Ⅲ, the feces of the joint group were dryer and harder than those of the control group (P<0.05). The bowel movements in the two groups after treatment were both increased significantly than before, and the stool was more softened than before (P<0.05). The bowel movements in the joint group [(4.81± 1.43),(4.81±1.468) per week] were higher than those in the control group [(3.97±1.58),(4.03±1.33) per week] at the 3rd and 4th week after treatment (P<0.05). The average BSFS in the two groups were type IV at the 4th week after treatment, there was no significant difference between the two groups. There was no significant difference between the two groups in the clinical effect at the 4th week after treatment （P>0.05）. There was more significant difference between the two groups in the clinical effect at the 8th week after treatment （97.37% vs 62.50%，P＜ 0.01）.ConclusionBifidobacterium lactis Bb12 is effective in the adjuvant treatment of functional constipation in children.

参考文献/References:

[1]吕峻峰,熊勇,刘玉玲，等.儿童及青少年功能性便秘流行病学调查及危险因素分析[J]. 中国妇幼保健,2012,27 (21):3301-3303.
[2]Malowitz S, Green M, Karpinski A, et al. Age of onset of functional constipation [J]. J Pediatr Gastroenterol Nutr, 2016,62(4): 600-602.
[3]吴建霞，郭秀君.儿童功能性便秘生物反馈治疗研究进展[J]. 医学研究生学报,2012,25(3):327-329.
[4]胡会,肖咏梅,张婷.儿童功能性便秘的危险因素分析 [J]. 临床儿科杂志, 2015, 33(4): 306-308.
[5]Levy EI, Lemmens R, Vandenplas Y,et al. Functional constipation in children: challenges and solutions [J]. Pediatric Health Med Ther, 2017, 8: 19-27.
[6]苏静,林江.功能性便秘的发病机制及中西医治疗与离子通道关系的研究进展[J]. 东南国防医药,2018,20 (6):618-620.
[7]Tabbers MM, Dilorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN[J]. J Pediatr Gastroenterol Nutr, 2014, 58(2):258-274.
[8]Koppen IJ, Lammers LA, Benninga MA, et al. Management of functional constipation in children: therapy in practice[J]. Pediatric Drugs, 2015, 17(5): 349-360.
[9]Rondanelli M, Faliva MA, Perna S, et al.Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses[J]. Gut microbes, 2017, 8(6): 521-543.
[10]张新艳,付超,安琦，等.益生菌补充剂对饮食控制型妊娠期糖尿病患者胰岛素抵抗的影响[J]. 医学研究生学 报,2020,33(6):609-612.
[11]季国忠,王静静.细胞免疫及肠道益生菌治疗在肝癌治疗研究中的新进展[J]. 医学研究生学报,2019,32(7):673 -677.
[12]Zhai SX, Zhu LM, Qin S, et al. Effect of lactulose intervention on gut microbiota and short chain fatty acid composition of C57 BL/6J mice[J]. Microbiologyopen, 2018, 7(6): e612.doi: 10.1002/mbo3.612.
[13]Mao B, Li D, Ai C, et al. Lactulose differently modulates the composition of luminal and mucosal microbiota in C57BL/6J mice[J]. J Agric Food Chem, 2016, 64(31): 6240-6247.
[14]Prtty A, Rautava S, Kalliomki M. Probiotics on pediatric functional gastrointestinal disorders[J]. Nutrients, 2018, 10(12): 1836.
[15]Bu LN, Chang MH, Ni YH, et al. Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation[J]. Pediatr Int, 2007, 49(4): 485-490.
[16]Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study[J]. J Pediatr, 2010, 157(4): 598-602.
[17]Sadeghzadeh M, Rabieefar A, Khoshnevisasl P, et al. The effect of probiotics on childhood constipation: a randomized controlled double blind clinicaltrial[J]. Int J Pediatr，2014:937212. doi: 10.1155/2014/937212.
[18]Eskesen D, Jespersen L, Michelsen B, et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial[J]. Br J Nutr, 2015, 114(10): 1638-1646.
[19]de Meij TG, de Groot EF, Eck A, et al. Characterization of microbiota in children with chronic functional constipation[J/OL]. PLoS One, 2016, 11(10): e0164731. doi:10.1371/journal.pone.0164731.

相似文献/References:

[1]李会丽,李传生,崔正霞.门冬氨酸-鸟氨酸联合乳果糖灌肠治疗肝硬化肝性脑病疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2012,14(02):190.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-12-15